Migraine Drugs Segmentation
The treatment type segment in migraine drugs market is segmented into abortive treatment and preventive treatment. Based upon segmentation by treatment type, the market for abortive segment is anticipated to dominate the market on the account of ease of self administration for the people having vomiting or nausea related to migraine. In addition, abortive treatment works quickly when used at the first sign of migraine. These factors are forecasted to drive the growth of the market.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment Type |
|
|
By Route of Administration |
|
|
By End Users |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of migraine drugs is assessed at USD 6.83 billion.
Migraine Drugs Market size was over USD 6.22 billion in 2024 and is projected to reach USD 25.91 billion by 2037, growing at around 11.6% CAGR during the forecast period i.e., between 2025-2037.
North America industry is expected to dominate majority revenue share by 2037, due to increasing adoption of novel therapies and high prevalence of migraine.
The major players in the market are Pfizer Inc., Eli Lilly and Company, Eisai Co. Ltd., Amneal Pharmaceuticals Inc., Abbott Laboratories, Novarties International AG, Amgen Inc., Teva Pharmaceuticals Industries, Endo International Plc., and others.
